对 T 细胞疗法耐药的多发性骨髓瘤细胞表现出 CD45+ 免疫逃逸表型

Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype.

多发性骨髓瘤免疫治疗序贯的真实世界证据：既往 GPRC5D 靶向治疗后 BCMA 靶向双特异性抗体可带来持久缓解

Real-World Evidence of Immunotherapy Sequencing in Multiple Myeloma: Durable Responses With BCMA-Targeting Bispecific Antibodies Following Prior GPRC5

靶向 BCMA 的双特异性抗体为经靶向 GPRC5D 的双特异性抗体治疗后进展的患者提供了一种有效且耐受性良好的治疗选择，支持该序贯方案作为一种有前景策略的可行性。

国际骨髓瘤工作组免疫治疗委员会关于多发性骨髓瘤治疗中免疫治疗序贯的推荐

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.

联合 BCMA 靶向 CAR-T 细胞与 TCR 工程化 T 细胞治疗以预防多发性骨髓瘤免疫逃逸

Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma.

使用 CAR 与 TCR 转基因 T 细胞过继细胞治疗多发性骨髓瘤：应答与耐药

Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance.